
Chronic Obstructive Pulmonary Disease - Pipeline Insight, 2024
Description
Chronic Obstructive Pulmonary Disease - Pipeline Insight, 2024
DelveInsight’s, “Chronic Obstructive Pulmonary Disease - Pipeline Insight, 2024” report provides comprehensive insights about 65+ companies and 70+ pipeline drugs in Chronic Obstructive Pulmonary Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Chronic Obstructive Pulmonary Disease: Overview
Chronic obstructive pulmonary disease (COPD) is a common, preventable, and treatable disease. It is a poorly reversible lung disease characterized by persistent and progressive airflow limitation caused by an enhanced chronic inflammatory response in the airways and the lungs due to noxious particles or gases. Also, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) defines a COPD exacerbation as an event in the natural course of the disease that is characterized by a change in the patient’s baseline dyspnea, cough, and sputum that is beyond normal day-to-day variations, is acute in onset, and warrants a change in regular medication. Predominantly, COPD includes emphysema and chronic bronchitis.
The pathogenesis of COPD is based on the innate and adaptive inflammatory immune response to inhaling toxic gases and particles. Although smoking is the main cause of this type of inhalation injury, many other environmental and occupational exposures can also contribute to the pathology of COPD. The immune-inflammatory changes associated with COPD are related to the tissue repair and remodeling process, which increases mucus production and causes emphysema destruction of the lung gas exchange surface. The common form of emphysema in smokers begins in the respiratory bronchioles, near the thickened and narrowed bronchiole, which becomes the main site of COPD obstruction. The mechanism allows the small airways to thicken, which is so close to the lung tissue that it undergoes emphysema destruction.
Although many factors are related to survival in COPD patients, the patient's age and baseline bronchodilator FEV1 are the best predictors of mortality. The presence of mild obstructive airway disease does not indicate a progressive downward course or shorter survival. Mortality in patients with baseline bronchodilator FEV1 greater than or equal to 50% of the predicted value was only slightly higher than in a group of healthy smokers. The age of the patient and the severity of the injury must match closely because younger people and people with fewer injuries can live longer.
Currently, there is no cure for COPD; however, treatment can help slow the disease’s progression and symptoms. Smoking cessation is the best way to reduce COPD progression. Also, regular use of inhaled bronchodilators, either alone or in combination, to prevent and relieve symptoms is the mainstay of COPD management. There are several types of inhalers for COPD, but the main type comprises short-acting bronchodilator inhalers (used when needed to provide immediate symptom relief, especially in mild COPD) and long-acting bronchodilators (used to provide relief for a long duration).
""Chronic Obstructive Pulmonary Disease- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic Obstructive Pulmonary Disease pipeline landscape is provided which includes the disease overview and Chronic Obstructive Pulmonary Disease treatment guidelines. The assessment part of the report embraces, in depth Chronic Obstructive Pulmonary Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Obstructive Pulmonary Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Obstructive Pulmonary Disease R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Obstructive Pulmonary Disease.
This segment of the Chronic Obstructive Pulmonary Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Chronic Obstructive Pulmonary Disease Emerging Drugs
- Benralizumab: AstraZeneca
- Dupilumab: Sanofi
- Tezepelumab: Amgen
- SNG001: Synairgen
- GSK3923868: GlaxoSmithKline
Further product details are provided in the report……..
Chronic Obstructive Pulmonary Disease: Therapeutic Assessment
This segment of the report provides insights about the different Chronic Obstructive Pulmonary Disease drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Chronic Obstructive Pulmonary Disease
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Intramuscular
- Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Product Type
Chronic Obstructive Pulmonary Disease: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chronic Obstructive Pulmonary Disease therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic Obstructive Pulmonary Disease drugs.
Chronic Obstructive Pulmonary Disease Report Insights
- Chronic Obstructive Pulmonary Disease Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Chronic Obstructive Pulmonary Disease drugs?
- How many Chronic Obstructive Pulmonary Disease drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic Obstructive Pulmonary Disease?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chronic Obstructive Pulmonary Disease therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Chronic Obstructive Pulmonary Disease and their status?
- What are the key designations that have been granted to the emerging drugs?
- Sanofi
- AstraZeneca
- Amgen
- Synairgen
- GlaxoSmithKline
- Eisai
- Meridigen Biotech
- Chiesi
- EmeraMed Limited
- Verona Pharma
- Tetherex Pharmaceuticals
- Mereo BioPharma
- Lemborexant
- UMC119-06
- CHF5259
- Emeramide
- Ensifentrine
- SNG001
- GSK3923868
- Benralizumab
- Dupilumab
- Tezepelumab
- SelK2
- BCT197
Table of Contents
220 Pages
- Introduction
- Executive Summary
- Chronic Obstructive Pulmonary Disease: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Chronic Obstructive Pulmonary Disease– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Benralizumab: AstraZeneca
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Tezepelumab: Amgen
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- GSK3923868: GlaxoSmithKline
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Chronic Obstructive Pulmonary Disease Key Companies
- Chronic Obstructive Pulmonary Disease Key Products
- Chronic Obstructive Pulmonary Disease- Unmet Needs
- Chronic Obstructive Pulmonary Disease- Market Drivers and Barriers
- Chronic Obstructive Pulmonary Disease- Future Perspectives and Conclusion
- Chronic Obstructive Pulmonary Disease Analyst Views
- Chronic Obstructive Pulmonary Disease Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.